Collection and Measurement of Biomarkers in Prostate Cancer Radiotherapy Patients
(COMBINE Trial)
Trial Summary
What is the purpose of this trial?
The purpose of this research study is to learn about: 1) How standard radiation treatment to prostate (primary radiotherapy) or the pelvis after prostatectomy (postoperative radiotherapy) may cause changes in MRI and PET imaging traits that might be used in the future to predict response. 2) Comparison of such MRI and PET imaging traits with the number of circulating tumor cells (CTCs) present in the blood prior to treatment and the changes in these counts after treatment. 3) How MRI and PET imaging characteristics and changes are related to the expression of genes in the cancer tissue obtained before treatment from prostate biopsy or a prior prostatectomy before treatment. 4) How the response of prostate cancer treatment relates to the imaging and CTC changes.
Research Team
Alan Pollack, MD, PhD
Principal Investigator
University of Miami
Eligibility Criteria
Inclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Radiation Treatment
Participants receive standard radiation treatment to the prostate or pelvis after prostatectomy
Post-Treatment Monitoring
Quantitative imaging parameters and circulating tumor cell (CTC) changes are monitored
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Postoperative Radiotherapy
- Primary Radiotherapy
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Miami
Lead Sponsor
Bankhead-Coley Florida Biomedical Research Program
Collaborator